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Oesophageal Doppler Monitoring (ODM) is used clinically to optimise cardiac output 3 
(CO) and guide fluid therapy. Despite limited experimental evidence, it is assumed 4 
that increasing CO increases visceral microvascular blood flow (MBF). We used 5 
contrast-enhanced ultrasound (CEUS) to assess if ODM-guided optimisation of CO 6 
altered MBF. 7 
 8 
Methods 9 
Sixteen healthy male volunteers (62±3.4 years) were studied. Baseline 10 
measurements of CO were recorded via ODM. Hepatic and renal MBF were 11 
assessed via CEUS. Saline 0.9% was administered to optimise CO according to a 12 
standard protocol and repeat CEUS performed. Time-intensity curves were 13 
constructed, allowing organ perfusion calculation via time to 5% perfusion (TT5). 14 
MBF was assessed via organ perfusion rise time (5-95%) (RT). 15 
 16 
Results 17 
CO increased (4535 ± 241 ml/min vs 5442 ± 329ml/min, p<0.0001) following fluid 18 
administration, while time to renal (22.48 ± 1.19secs. vs. 20.79 ±1.31secs; p=0.03), 19 
but not hepatic (28.13 ± 4.48s. vs 26.83 ±1.53secs; p=0.15) perfusion decreased. 20 
Time to renal perfusion was related to CO (renal: r=-0.43, p=0.01). Hepatic nor renal 21 
































































RT altered following fluid administration (renal: 9.03 ± 0.86 vs. 8.93 ± 0.85secs 22 
p=0.86; hepatic: 27.86 ± 1.6 vs. 30.71 ± 2.19secs, p=0.13). No relationship was 23 
observed between changes in CO and MBF in either organ (renal: r=-0.17, p=0.54; 24 
hepatic: r=-0.07, p=0.80).  25 
 26 
Conclusions 27 
ODM optimised CO reduces time to renal perfusion but does not alter renal or 28 
hepatic MBF. A lack of relationship between microvascular visceral perfusion and 29 
CO following ODM-guided optimisation may explain the absence of improved clinical 30 
outcome with ODM monitoring. 31 
 32 
Trial Registration 33 
The study was registered at clinicaltrials.gov (reference number NCT02167178). 34 
Keywords 35 
Contrast-enhanced Ultrasound, CEUS, oesophageal Doppler, healthy volunteers, 36 






































































The ability to measure cardiovascular performance is integral to anesthetic and 43 
critical care practice. Traditional clinical monitoring modalities such as blood 44 
pressure (BP), heart rate (HR), and central venous pressure fail to provide a 45 
continuous, accurate assessment of microvascular haemodynamic performance or 46 
identify instances of tissue hypoperfusion [1, 2] with uncorrected tissue 47 
hypoperfusion increasing surgical morbidity and mortality [3].  48 
 49 
Alternative monitoring techniques provide estimates of stroke volume (SV) in an 50 
attempt to guide fluid and vasoactive drug therapy and optimise tissue perfusion. 51 
Traditional measurement of SV involved insertion of a pulmonary artery flotation 52 
catheter (PAFC) and measurement via thermodilution techniques. PAFC use has 53 
declined over the past decade, primarily due to concerns about the complications of 54 
insertion and an absence of studies demonstrating clinical benefit [4, 5]. 55 
Consequently, less invasive techniques for measuring SV have been developed. 56 
Thermodilution, however, remains the gold standard for the assessment of SV 57 
against which new monitors are compared [6].  58 
 59 
The oesophageal Doppler monitor (ODM) is one such less invasive monitoring 60 
device. ODM has been validated against PAFC thermodilution techniques in a 61 
number of patient populations [7]. ODM has allowed a number of algorithms to be 62 
































































developed to guide intravenous (IV) fluid administration [8-11]. It is recommended for 63 
intra-operative use by the National Institute for Health and Care Excellence (NICE) 64 
and has been advocated for use in awake patients [12].  65 
 66 
SV and cardiac output (CO) are intrinsically linked, with CO the product of SV and 67 
HR. Whilst ODM permits reproducible estimates of CO, it is unclear what benefits 68 
are brought to the patient by its use. Despite studies initially suggesting a reduction 69 
in morbidity and mortality with ODM guided perioperative fluid therapy [13, 14], 70 
recent randomised controlled trials and meta-analysis’ have questioned these 71 
conclusions [15, 16]. CO monitoring provides more information than pressure-related 72 
measures, but it is limited to the assessment of changes in whole-body 73 
haemodynamics. The complexity of regulatory mechanisms that have been observed 74 
to impact upon blood flow through the abdominal organs would suggest that no 75 
simple relationship can exist between CO and visceral perfusion. This challenges the 76 
notion that clinical benefit will directly result from maximisation of CO. Therefore, 77 
assessment of visceral microvascular blood flow (MBF) (e.g. in the gastrointestinal 78 
mucosa during and after abdominal surgery) may provide more relevant end points 79 
for guiding fluid therapy to reduce perioperative visceral hypoperfusion. 80 
 81 
Contrast enhanced ultrasound (CEUS) is an imaging modality that can provide near-82 
real time imaging of perfusion within viscera at a capillary level. CEUS has been 83 
validated for accurately measuring visceral blood flow against a number of proven 84 
technologies. Numerous in-vitro and in vivo studies, have validated the accuracy of 85 
































































CEUS in assessing microvascular blood flow, demonstrating close correlation with 86 
thermodilution [17], mechanically controlled flow [18] and end organ microvascular 87 
perfusion [19], [20] . 88 
 89 
CEUS utilises echogenic microspheres that return a characteristic echo pattern. 90 
During CEUS, intravenous administration of a bolus of the contrast agent permits 91 
construction of time-acoustic intensity (AI) curves. From these curves the time from 92 
bolus to 5% of peak AI (TT5) for each organ, pre- and post-fluid administration and 93 
rise time (RT), defined as the time taken to rise from 5-95% of the peak AI (Figure 1), 94 
may be calculated. This technique has previously been validated as a method of 95 
tracking changes in MBF of the intra-abdominal viscera [21, 22]. 96 
 97 
We hypothesised that administration of intravenous (IV) fluid to achieve ODM-guided 98 
CO optimisation would reliably track visceral perfusion in both liver and kidney of a 99 
healthy individual. 100 
  101 

































































The University of Nottingham Medical School Research Ethics Committee 103 
(A12012012) granted ethical approval for the study. The study was registered at 104 
clinicaltrials.gov (reference number NCT02167178) and conformed to the 105 
Declaration of Helsinki. Sixteen healthy male participants aged between 18 and 80 106 
years were recruited using a standard demographically targeted postal invite. 107 
Participants attended for a pre-study health screening appointment and written 108 
informed consent was obtained. Participants were excluded if they presented with: 109 
BMI <20 or >30 kg.m-2, recent acute coronary syndrome, use of β-blockers, 110 
cerebrovascular disease, metabolic disease, known malignancy, clotting dysfunction, 111 
previous oesophageal surgery or oesophageal varices, history of epistaxis or known 112 
sensitivity to SonoVue™. For subject demographics see Table 1. 113 
 114 
Subject preparation 115 
Subjects attended the University of Nottingham; Clinical, Metabolic and Molecular 116 
Physiology laboratories fasted for 12 hours of food and fluids. A medically qualified 117 
doctor was present throughout the study and subjects were continuously monitored 118 
with pulse oximetry (SpO2), electrocardiogram (ECG) and non-invasive blood 119 
pressure recording (NIBP). A 20G intravenous cannula was sited in the right ante-120 
brachial vein and an 18G in the left. Venous blood was drawn for measurement of 121 
haemoglobin concentration (Hb) and haematocrit (Hct). A trans-oesophageal 122 
Doppler probe (Deltex Medical, Chichester, UK) was inserted into the oesophagus 123 
via the nostril, following local anesthesia to the naso-pharynx with 10% lidocaine 124 
































































spray and 2% lidocaine gel (ClinMed Ltd, High Wycombe, United Kingdom). The 125 
probe was connected to a CardioQ Oesophageal Doppler Monitor (ODM) (Deltex 126 
Medical) and probe position was corrected to achieve an optimal Doppler flow signal. 127 
ODM placement was well tolerated by all subjects. 128 
 129 
Contrast agent 130 
SonoVue™ (Bracco SpA, Milan, Italy), an established contrast agent for quantitative 131 
CEUS [23] was used, with preparation as per the manufacturer’s instruction [24]. In 132 
brief, 25mg of lyophilised powder was reconstituted with 5ml of 0.9% sodium chloride 133 
solution (NaCl) in an SF6 atmosphere. 134 
 135 
Ultrasound settings 136 
A Philips iU22 ultrasound machine (Philips Healthcare, Reigate, UK) with a C5-1 137 
MHz curvilinear probe (Philips Healthcare) was used for all examinations, using dual 138 
contrast/tissue side-by-side mode. Cine recordings were made at 9Hz with a contrast 139 
resolution of C40, a working mechanical index (MI) of 0.04, a maximum depth of 140 
16cm and focus at 8-14cm. Gain was optimised for each subject. 141 
 142 
Experimental protocol 143 
Patients were placed in a semi-recumbent position. The ultrasound probe was 144 
positioned to allow concurrent imaging of the liver and right kidney with probe 145 
































































position manipulated to optimise visualised liver and renal parenchyma. Following 146 
optimisation the probe position was marked with ink to facilitate repeat visceral 147 
imaging. 148 
 149 
Once the probe was positioned and marked baseline recordings of SpO2, ECG, 150 
mean arterial blood pressure (MAP), HR and SV were made. CEUS was then 151 
performed by administering a rapid bolus of 0.5ml of SonoVue™ via the 20G 152 
cannula, immediately followed by a rapid flush of 5ml of 0.9% NaCl. At the same 153 
time, a continuous, real-time low MI ultrasound recording of the liver and kidney 154 
commenced, and continued for 2 minutes. After each 2 minute cycle, a 5 minute 155 
pause was observed, to allow elimination of microbubbles. During which time SpO2, 156 
MAP, SV and HR were again measured. This sequence was repeated three times. 157 
 158 
Subjects were then given a 250ml bolus of 0.9% NaCl solution as rapidly as possible 159 
via the 18G cannula with a 50ml syringe and 3-way tap used to facilitate rapid 160 
infusion of an accurate fluid volume. On completion of this bolus, SV, HR, NIBP and 161 
SpO2 were recorded. Repeat fluid boluses were administered and observations 162 
made until the SV no longer increased by >10%, at which point the SV was deemed 163 
optimal [11]. Median fluid administration to optimise SV was 1000ml (IQR 1000-164 
1000ml, range 1000-2000ml). Immediately after optimisation of SV a further set of 165 
CEUS recordings and cardiovascular observations were performed, using the 166 
protocol outlined above. A further blood sample was then taken for measurements of 167 
































































hemoglobin (Hb) and hematocrit (Hct). Patients were monitored for 30 minutes 168 
following completion of the study protocol (Figure 2).  169 
 170 
Image processing 171 
Ultrasound video files were analysed using QLAB™ software (Philips Healthcare). 172 
Regions-of-interest (ROI) were defined within liver and kidney images to allow 173 
computation of the mean pixel intensity within each ROI for each frame of the 174 
ultrasound loop (Figure 3). The ROI was chosen to ensure as large an area as 175 
possible was available for analysis, whilst avoiding tissue close to the capsule of 176 
each organ to minimise the effect of the subtle movement of these organs seen with 177 
respiration. Large hilar blood vessels were excluded from the ROI to achieve 178 
preferential assessment of microvascular haemodynamics. 179 
 180 
Image analysis 181 
For each bolus injection, ROI AI was calculated for liver and kidney from each frame 182 
(i.e. at 9Hz) and subsequently standardised to that organs maximum intensity. 183 
Standardised AI traces were smoothed and low-pass filtered by calculation of a 3 184 
second moving average. The resultant time–intensity trace was used to measure RT 185 
(time from 5-95% of peak AI) and TT5 (time from bolus to 5% of peak AI) for each 186 
organ pre- and post-fluid administration. Results were averaged across the 3 cycles 187 
recorded at each time-point. 188 
 189 
































































Cardiovascular parameter analysis 190 
Data for SV, MAP, HR, Hb, Hct and SpO2 were recorded as described above and 191 
data stored on an Excel spreadsheet (Microsoft Corporation, Redmond, Washington, 192 
USA). Mean values for each of these variables before and after SV optimisation 193 
were recorded. 194 
 195 
Statistics 196 
Sample size calculations required n=16 (for α=0.05, β=0.85), to detect a 30% 197 
change in hepatic microvascular blood flow, results we have been able to achieve for 198 
previous work looking at similar physiological systems. Statistical analysis was 199 
performed using GraphPad Prism™ v6.0 (La Jolla, CA. USA). Distribution of data 200 
was tested using Kolmogorov-Smirnov tests, with normal data expressed as mean ± 201 
standard error of the mean (SEM) and non-normal data as median ± interquartile 202 
range. Independent t-tests were applied to normal data and Mann-Whitney tests to 203 
non-normal data. Categorical values were compared using Fisher’s test. p<0.05 was 204 
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Results  210 
CO and SpO2 increased significantly following fluid administration (4535±241 vs. 211 
5442 ± 329 ml.min-1, P<0.0001; 96.9±0.4 vs. 97.8±0.3%, p<0.01, respectively), whilst 212 
Hb and Hct decreased (149±2.5 vs. 138.5±2.8 g.l-1, p<0.01; 0.441±0.01 vs. 213 
0.412±0.01, p<0.01, respectively). MAP and HR remained unchanged following fluid 214 
administration (105.3±2.4 vs. 106.3±2.8 mmHg, p=0.31; 61.8±1.8 vs. 62.1±1.9 bpm, 215 
p=0.54, respectively). 216 
 217 
Despite increases in CO and decreases in Hct following fluid administration, MBF 218 
was not altered by fluid administration in either the hepatic (RT: 27.86±1.6 vs. 219 
30.71±2.19 secs, p=0.13) or renal (RT: 9.03±0.86 vs. 8.93±0.85 secs, p=0.86) 220 
circulation (Figure 4). Likewise no relationship was observed between CO and MBF 221 
in either the kidney (r=-0.17, p=0.54) or liver (r=-0.07, p=0.8) (Figure 5). 222 
 223 
Time to renal perfusion decreased following fluid administration (TT5: 22.48±1.19 vs. 224 
20.79±1.31 secs, p= 0.03), whilst time to hepatic perfusion was unaltered (TT5: 225 
28.13±4.48 vs. 26.83±1.53 secs, p=0.15.).  Similarly time to renal, but not hepatic 226 
perfusion, was correlated with CO (renal: r=-0.43, p=0.01; hepatic: r=-0.21, p=0.26) 227 
(Figure 5). 228 
 229 
There was no significant relationship observed between change in cardiac output (∆ 230 
CO) and change in renal rise time (∆ renal RT), (r=-0.17 and p=0.27). A significant 231 
































































correlation was observed between ∆ CO and change in renal TT5 (∆ TT5), (r=-0.50, 232 
p=0.05; Figure 6).  233 
 234 
In the hepatic circulation, ∆ CO did not correlate with change in hepatic rise time (∆ 235 
hepatic RT), (r=0.07, p=0.40); nor with change in hepatic TT5 (∆ hepatic TT5), 236 
(r=0.09, p=0.36). 237 
 238 
Discussion 239 
In this study we use the novel technologies of CEUS and ODM to explore the 240 
relationship between CO and MBF. As expected fluid administration reliably 241 
increased CO, reduced time to renal perfusion and reduced haematocrit. Despite 242 
these changes in macrocirculatory variables, CO showed no significant correlation 243 
with measures of MBF in either renal or hepatic circulations. 244 
   245 
The relationship between venous filling and SV is relatively simple, and is described 246 
by the Frank-Starling law; essentially, higher filling pressures lead to greater preload, 247 
and hence more forceful contraction of myocardial fibers, resulting in a greater SV 248 
and thus CO [25] (other afterload mediated effects remaining constant over the short 249 
period of this study).  250 
 251 
































































The relationship between MBF and fluid administration is more complex, with 252 
multiple factors affecting perfusion of the liver and kidney. Strong autoregulatory 253 
mechanisms exist within the kidney to maintain a constant blood flow across a range 254 
of blood pressures and volaemic conditions [26]. In this healthy volunteer study 255 
these mechanisms are likely to have remained intact.  256 
 257 
The autoregulatory ability of the liver is less robust; with the main determinants of 258 
hepatic perfusion being sympathetic nervous system activity, circulating 259 
catecholamines, and the interaction between the arterial and portal venous 260 
circulations (the hepatic arterial buffer response) [27]. In hypovolaemia, large 261 
volumes of blood may be mobilised from the splanchnic circulation to preserve 262 
perfusion of the brain, heart and musculature [28]. Hypovolaemia reduces splanchnic 263 
perfusion, portal venous flow and hence hepatic blood flow and these effects persist 264 
for some time after restoration of euvolaemic [29]. 265 
 266 
These complex interactions challenge simplistic assumptions that SV and CO are 267 
key determinants of MBF. As microvascular perfusion is vital for normal organ 268 
function and tissue healing, including for example, at anastomoses, this lack of 269 
response to SV optimisation with intravenous fluid may help to explain why recent 270 
publications and meta-analyses have failed to show a consistent reduction in 271 
morbidity or mortality when ODM-guided fluid management protocols have been 272 
used in the perioperative period [15, 16].  273 
 274 
































































There are a number of limitations to this present study. Firstly, the use of healthy 275 
subjects may limit the applicability of the findings to the perioperative and critical 276 
care patient. Also in an attempt to somewhat mirror a clinical population subjects 277 
were taken from a predominantly older male age range, which may limit the 278 
conclusions of this study to a wider clinical group. Subjects were hypovolaemic after 279 
a 12-hour fast, as evidenced by the increase in SV with intravenous administration of 280 
c. 1L of IV crystalloid, and this reflects modern surgical practice [30]. However, the 281 
impact of anaesthesia has not been addressed in this study. Additionally, as ODM 282 
measurement of cardiac output varies with change in subject position, it was decided 283 
that subjects should studied in a semi-recumbent position to aid subject comfort. 284 
This position corresponds to the recommended positioning for patients on the 285 
intensive care unit. Importantly participant position was not altered between CEUS 286 
measurements, in order to reduce any error due to change in subject or probe 287 
positioning. However, findings may therefore not be relevant in a population in a fully 288 
recumbent position.  289 
The absolute values of CO measured in this study by ODM are in several instances 290 
around 3L per minute. This is lower than would be expected for a healthy male 291 
population and may relate to position and relatively increased age of the study 292 
volunteers. In addition, although ODM measurements were taken by clinicians, 293 
experienced and skilled in the use of ODM monitoring, there are undoubted 294 
limitations to the use of ODM to acquire exact discrete measures of cardiac output. 295 
Furthermore, ODM calculates the volume of blood transiting the descending aorta 296 
and employs a number of assumptions to calculate cardiac output from this, while by 297 
necessity excluding perfusion of head and upper limbs. Although these factors may 298 
































































have resulted in lower than expected numerical values for CO the ability of the ODM 299 
to accurately determine changes in cardiac output is preserved.  300 
Efforts were made to ensure consistency of tissue imaged throughout. Despite this, 301 
absolute probe fixation is not possible and small movements, such as with 302 
respiration, induce movement artifact to CEUS measures [31]. To overcome this 303 
problem, we employed a validated time-based surrogate for tissue perfusion, the RT, 304 
which is more robust to small variations in the imaged tissue [22]. This technique 305 
does provide a less comprehensive assessment of microvascular status than 306 
techniques that generate volumetric data [21, 31], such as microbubble destruction-307 
replenishment [18], but is ultimately more reliable in this cohort of subjects. 308 
 309 
A sample size calculation was determined for the primary hypothesis of a 30% 310 
change in hepatic microvascular blood flow following fluid optimisation. Despite ODM 311 
assessed fluid optimisation we found no significant change in hepatic microvascular 312 
blood flow. Of note, the study was not powered to expose a relationship between the 313 
change in CO and change in MVBF before and after fluid optimization and thus may 314 
have been underpowered for detect such a relationship. It is important however to 315 
note, that there was also no suggestion of a clear relationship between CO and RT 316 
(r=-0.07 (hepatic), r=-0.17 (renal)). 317 
Conclusion 318 
This study describes a bolus method for comparison of ODM-derived CO and CEUS-319 
derived measures of renal and hepatic perfusion in the healthy, awake subject. Our 320 
data suggest that ODM guided fluid administration reliably increases CO and time to 321 
































































renal perfusion, but that such changes do not increase MBF within hepatic or renal 322 
parenchyma. This challenges the assumption that optimisation of CO improves 323 
abdominal visceral perfusion. The inability of ODM-guided fluid management to 324 
increase renal and hepatic MBF may be a factor in the lack of improved clinical 325 
outcome with ODM monitoring.326 
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Table 1.; Subject demographic data 
 Mean Standard Deviation 
Age (years) 62 ±13.6 
Height (m) 1.76 ±0.06 
Weight (kg) 83.8 ±10.3 
BMI (kg/m2) 27.1 ±2.4 
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Legends for Figures 
Figure 1. Example time-intensity curve for the liver. Dotted lines show 5 and 95% of 
the maximum values. In this example, the 5% value is 0.037 arbitrary units (AU), 
occurring at 18.41 seconds (TT5). The 95% value is 0.699 AU, occurring at 32.83 
seconds, resulting in a rise time of 14.42 seconds. 
 
Figure 2. Outline of study protocol. SV, Stroke Volume; CEUS, Contrast Enhanced 
Ultrasound; Hb, Haemoglobin; Hct, Haematocrit; SpO2, Oxygen saturation;  NIBP, 
Non-invasive blood pressure; ECG, Electrocardiogram. 
 
Figure 3. Example of region of interest quantification in QLAB™ software. Top - 
regions of interest defined on the contrast-enhanced image of the liver (red) and 
kidney (yellow), Bottom - graph of acoustic intensity against time, as output from 
QLAB™ for liver (red) and kidney (yellow). 
 
Figure 4. Normalised Cardiac output, renal rise-time and hepatic rise-time before and 
after fluid optimisation, **** significant difference, pre- vs. post-fluid administration, 
p<0.0001. 
 
Figure 5. Rise time (RT, sec) within the hepatic (A) and renal (B) microcirculations 
plotted against cardiac output (hepatic r= -0.07, p=0.8;, renal r= -0.17, p=0.54). Time 
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to 5% perfusion (TT5, sec) within the hepatic (C) and renal (D) microcirculations 
plotted against cardiac output (hepatic r=-0.21, p=0.26:, renal r=-0.43, p=0.01). 
Figure 6. Change in rise time (∆ RT, sec) within the hepatic (A) and renal (B) 
microcirculation plotted against change in cardiac output (∆ CO, l/min). Change in 
Time to 5% perfusion (∆ TT5, sec) within the hepatic (C) and renal (D) 
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Figure 1. Example time-intensity curve for the liver. Dotted lines show 5 and 95% of the maximum values. 
In this example, the 5% value is 0.037 arbitrary units (AU), occurring at 18.41 seconds (TT5). The 95% 
value is 0.699 AU, occurring at 32.83 seconds, resulting in a rise time of 14.42 seconds.  
 
 

































































































































Figure 3. Example of region of interest quantification in QLAB™ software. Top - regions of interest defined 
on the contrast-enhanced image of the liver (red) and kidney (yellow), Bottom - graph of acoustic intensity 
against time, as output from QLAB™ for liver (red) and kidney (yellow).  
 
 

































































Figure 4. Normalised Cardiac output, renal rise-time and hepatic rise-time before and after fluid 
optimisation, **** significant difference, pre- vs. post-fluid administration, p<0.0001.  
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